Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors

By S. Boutin, Virginie Monteilhet, P. Véron, C. Leborgne, O. Benveniste, M. Montus, C. Masurier. Human Gene Therapy, 2010

922 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/595e42dd7d01ea0d4840b5afe5f7a14d21cbbe0b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. F. Mingozzi

Citations in the corpus

• Immune responses to AAV vectors: overcoming barriers to successful gene therapy. (2013, neutral): “21 Use repeated plasma exchange cycles to adsorb immunoglobulins and therefore reduce the anti-AAV antibody titer.”
• Emerging Issues in AAV-Mediated In Vivo Gene Therapy (2017, background): “One key concept to keep in mind when studying immune responses to AAV vectors is that the viral capsid is identical or nearly identical to the capsid of the wild-type virus, to which humans are exposed.(4,61,62) Thus, it is expected that the host immune responses”